Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study

Circulation Research

Volumn 118, Issue 1, 2016, Pages 73-82

  Shamburek, Robert D ^a   Bakker Arkema, Rebecca ^b   Shamburek, Alexandra M ^a   Freeman, Lita A ^a   Amar, Marcelo J ^a   Auerbach, Bruce ^b   Krause, Brian R ^b   Homan, Reynold ^b   Adelman, Steve J ^c   Collins, Heidi L ^c   Sampson, Maureen ^a   Wolska, Anna ^a   Remaley, Alan T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b AlphaCore Pharma   (United States)

^c Vascular Strategies LLC   (United States)

Author keywords

acute coronary syndrome; cardiovascular diseases; cholesterol; cholesterol, HDL; lecithin cholesterol acyltransferase; lecithin cholesterol acyltransferase deficiency

Indexed keywords

PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RECOMBINANT PROTEIN;

ADULT; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RASH; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RECOMBINANT PROTEINS;

EID: 84955177348     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306223     Document Type: Article

References (38)

1. Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT. Lecithin cholesterol acyltransferase: an anti-or pro-atherogenic factor Curr Atheroscler Rep. 2011;13:249-256. doi: 10.1007/s11883-011-0171-6.
2. Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, highdensity lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med. 2010;20:50-53. doi: 10.1016/j.tcm.2010.03.007.
3. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009;16:163-171.
4. Rashid S, Patterson BW, Lewis GF. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans J Lipid Res. 2006;47:1631-1642. doi: 10.1194/jlr. R600008-JLR200.
5. Kane JP, Malloy MJ. Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol. 2012;23:367-371. doi: 10.1097/MOL.0b013e328353eef1.
6. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis. 2012;222:299-306. doi: 10.1016/j.atherosclerosis. 2011.11.034.
7. Rousset X, Vaisman B, Auerbach B, Krause BR, Homan R, Stonik J, Csako G, Shamburek R, Remaley AT. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther. 2010;335:140-148. doi: 10.1124/jpet.110.169540.
8. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
9. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919. doi: 10.1161/CIRCULATIONAHA.111.066589.
10. Czarnecka H, Yokoyama S. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. J Biol Chem. 1996;271:2023-2028.
11. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56:1128-1137. doi: 10.1373/clinchem.2009.139931.
12. Kunnen S, Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis J Lipid Res. 2012;53:1783-1799. doi: 10.1194/jlr. R024513.
13. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248-E256. doi: 10.1210/jc.2011-1846.
14. Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol. 2013;24:480-486. doi: 10.1097/MOL.0000000000000020.
15. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300. doi: 10.1001/jama.290.17.2292.
16. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675-1682. doi: 10.1001/jama.297.15.jpc70004.
17. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670-2676.
18. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185-2191. doi: 10.1161/01.ATV.0000183727.90611.4f.
19. Amar MJ, Shamburek RD, Vaisman B, Knapper CL, Foger B, Hoyt RF Jr, Santamarina-Fojo S, Brewer HB Jr, Remaley AT. Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metabolism. 2009;58:568-575. doi: 10.1016/j.metabol.2008.11.019.
20. Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH, Rader DJ. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation. 2009;120:160-169. doi: 10.1161/CIRCULATIONAHA.108.825109.
21. Hoeg JM, Santamarina-Fojo S, Bérard AM, Cornhill JF, Herderick EE, Feldman SH, Haudenschild CC, Vaisman BL, Hoyt RF Jr, Demosky SJ Jr, Kauffman RD, Hazel CM, Marcovina SM, Brewer HB Jr. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents dietinduced atherosclerosis. Proc Natl Acad Sci USA. 1996;93:11448-11453.
22. Zhou M, Sawyer J, Kelley K, et al. Lecithin cholesterol acyltransferase promotes reverse cholesterol transport and attenuates atherosclerosis progression in new zealand white rabbits. Circulation. 2009;120:S1175.
23. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
24. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45:1594-1607. doi: 10.1194/jlr.M300511-JLR200.
25. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC lipoprotein and vascular diseases division working group on best practices. Clin Chem. 2013;59:752-770. doi: 10.1373/clinchem.2012.196733.
26. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813-2820. doi: 10.1161/ATVBAHA.112.300133.
27. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50:S189-S194. doi: 10.1194/jlr. R800088-JLR200.
28. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010;21:229-238.
29. Cho KH, Shin DG, Baek SH, Kim JR. Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp Mol Med. 2009;41:67-76. doi: 10.3858/emm.2009.41.2.009.
30. Ahsan L, Ossoli AF, Freeman LA, Vaisman BL, Amar MJ, Shamburek RD, Remaley AT. Role of lecithin: cholesterol acyltransferase in HDL metabolism and atherosclerosis. In: Komoda T, ed. The HDL Handbook: Biological Functions and Clinical Implications. New York: Elsevier; 2014:159-194.
31. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res. 2015;116:1133-1142. doi: 10.1161/CIRCRESAHA.116.305485.
32. Duivenvoorden R, Holleboom AG, van den Bogaard B, Nederveen AJ, de Groot E, Hutten BA, Schimmel AW, Hovingh GK, Kastelein JJ, Kuivenhoven JA, Stroes ES. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. J Am Coll Cardiol. 2011;58:2481-2487. doi: 10.1016/j.jacc.2010.11.092.
33. Zhang AH, Gao S, Fan JL, Huang W, Zhao TQ, Liu G. Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett. 2004;570:25-29. doi: 10.1016/j. febslet.2004.06.017.
34. Van Craeyveld E, Lievens J, Jacobs F, Feng Y, Snoeys J, De Geest B. Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther. 2009;16:757-765. doi: 10.1038/gt.2009.8.
35. Miida T, Obayashi K, Seino U, Zhu Y, Ito T, Kosuge K, Hirayama S, Hanyu O, Nakamura Y, Yamaguchi T, Tsuda T, Saito Y, Miyazaki O, Nakamura Y, Okada M. LCAT-dependent conversion rate is a determinant of plasma prebeta1-HDL concentration in healthy Japanese. Clin Chim Acta. 2004;350:107-114. doi: 10.1016/j.cccn.2004.07.014.
36. Föger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt RF, Brewer HB Jr, Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999;274:36912-36920.
37. Solaji-Bozicevi N, Stavljeni-Rukavina A, Sesto M. Lecithincholesterol acryltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig. 1994;72:951-956.
38. Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab. 2008;93:4860-4866. doi: 10.1210/jc.2008-1213.